Multiple Myeloma
Key Points
Key Points
- In 2018, an estimated 30,770 new cases of multiple myeloma will be diagnosed in the United States, representing 1.8% of all new cancer cases.
- The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
- Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
- The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...eatment...
Transplant Elig...
...should be referred to a transplant center to det...
...age and renal function should not be...
...imen and number of cycles remain u...
...front transplant should be offered to all transpla...
...s associated with stem cell toxicity, such as melp...
...cell collection (sufficient for more than...
...el of minimal response required to procee...
...melphalan is the recommended conditioning regime...
...em autologous SCT should not be ro...
...ge or delayed SCT may be used as consol...
...neic transplant for multiple myeloma is not routi...
Consolidation therapy is not routinely recommen...
...mide maintenance therapy should be...
...intolerant of or unable to receive lenali...
...tients, maintenance therapy with a proteaso...
...s insufficient evidence to make modi...
...quality and depth of response should be...
...al of initial therapy for transplant eligible pati...
...is recommended that depth of response be...
...low dose CT scan has been shown to be superio...
...nsplant Ineligible...
...ment recommendations for patients with mult...
...treatment for patients with multiple myel...
...herapies for patients with multipl...
...ysicians/patients should balance the poten...
...therapy should be offered over fixed duration...
...of initial therapy for transplant ineligible...
Depth of response for all patients shoul...
...cient evidence to support change in type an...
...pon initiation of therapy, one shoul...
...is recommended that patients be mon...
...elapsed Disea...
...for biochemically relapsed myeloma should be indi...
...clinically relapsed patients with symptoms due...
...apy should be administered on first re...
...f relapsed multiple myeloma may be continue...
...therapies should be taken into consideration...
...tem cell transplantation, if not recei...
...he risk status of the patients shou...
...eat risk assessment at the time of...
...sment of other risk factors such as re...
...ts with genetic high-risk disease a triplet combin...
...h renal insufficiency, drugs should be modifi...
...h plasma cell leukemia or extra medullary diseas...
The IMWG revised response criteria should be...
...e parameters need to be followed including light...
...xcluding marrow and imaging should be confirmed as...
...sessment should be performed after one cycle o...
...lgorithm On Management of Patients with...
...le 1. Drugs Used in the Management of Patients Wit...
...ble 2. Diagnostic Criteria for Active...
...vised International Staging System (R-ISS)Hav...
...Comparison of Select Risk Prediction Models Re...
...MWG Response CriteriaHaving trouble viewing table?...
...6. Estimated Cost of Drugs for Multiple M...